Detailed Analysis of the Scope and Claims of United States Patent 5,002,953
Introduction
United States Patent 5,002,953, filed on November 27, 1987, and granted on March 26, 1991, pertains to novel substituted-thiazolidinedione derivatives. These compounds have been discovered to exhibit improved blood-glucose lowering activity and are of significant interest in the treatment of metabolic disorders.
Background and Prior Art
The patent builds upon earlier research and patents related to thiazolidinedione derivatives, which have been disclosed for their hypoglycaemic and hypolipidaemic activities. Prior art includes European Patent Applications and publications such as Chem. Pharm. Bull 30 (10) 3580-3600, which also explore the therapeutic potential of these compounds[1].
Chemical Structure and Composition
The patent describes a class of compounds that fall within specific chemical formulas. These compounds are characterized by their thiazolidinedione ring structure, with various substitutions that enhance their therapeutic efficacy. Key components include:
- A1: A substituted or unsubstituted aromatic heterocyclyl group.
- R1: A hydrogen atom, an alkyl group, an acyl group, an aralkyl group, or a substituted or unsubstituted aryl group.
- R8 and R9: Independently representing hydrogen, halogen, substituted or unsubstituted alkyl, or alkoxy groups.
- X: Representing oxygen or sulphur[1].
Claims
The patent includes several claims that define the scope of the invention:
- Claim 1: A compound of formula (I) or a tautomeric form thereof, and/or a pharmaceutically acceptable salt or solvate thereof.
- Claim 2: A pharmaceutical composition comprising a non-toxic effective amount of the compound of formula (I) or its tautomeric form.
- Claim 3: A process for preparing the compounds of formula (I).
- Claim 4: The use of the compounds and compositions in medicine, particularly for treating disorders of metabolism such as hyperglycemia and hyperlipidemia[2].
Therapeutic Applications
The compounds described in the patent are primarily intended for their hypoglycaemic and hypolipidaemic activities. They are useful in the treatment of metabolic disorders, including diabetes and hyperlipidemia. The therapeutic efficacy of these compounds makes them valuable in the management of cardiovascular diseases and other metabolic syndromes[1].
Patent Landscape
Classification and Categorization
The patent is classified under various categories in the International Patent Classification (IPC) system, including:
- C07D277/00: Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings.
- A61P3/00: Drugs for disorders of the metabolism.
- A61P9/00: Drugs for disorders of the cardiovascular system[1].
Related Patents and Publications
The patent is part of a broader landscape of research and development in thiazolidinedione derivatives. Other patents and publications, such as European Patent Applications and scientific journals, contribute to the understanding and application of these compounds[1].
Patent Analytics and Claim Coverage
To fully understand the protective scope of this patent, patent analytics tools can be employed. These tools help in tracking patents by claims and scope concepts, identifying gaps or opportunities in intellectual property protection. For example, a Claim Coverage Matrix can categorize patents by claims and overarching scope concepts, facilitating a comprehensive analysis of the patent landscape[3].
Valuation of the Patent
The value of a patent like US 5,002,953 can be determined using various methods, including cost, income, and market approaches. The income approach, which considers the future benefits provided by the patent, is particularly relevant. The market value can be estimated by looking at what a willing buyer would pay for similar assets. For instance, significant patent deals, such as the Google-Motorola acquisition, highlight the high value placed on patents in the technology and pharmaceutical sectors[4].
Expiration and Legal Status
The patent has expired, as indicated by its legal status. This means that the exclusive rights to the invention are no longer in effect, and the technology is now in the public domain. However, the knowledge and innovations derived from this patent continue to influence current research and development in the field of metabolic disorder treatments[1].
Conclusion
United States Patent 5,002,953 represents a significant contribution to the field of metabolic disorder treatments through its novel substituted-thiazolidinedione derivatives. The detailed analysis of its scope, claims, and patent landscape provides a comprehensive understanding of its importance and impact.
Key Takeaways
- Novel Compounds: The patent introduces new thiazolidinedione derivatives with enhanced therapeutic efficacy.
- Therapeutic Applications: These compounds are useful in treating hyperglycemia, hyperlipidemia, and other metabolic disorders.
- Patent Claims: The patent includes claims for the compounds, pharmaceutical compositions, preparation processes, and medical uses.
- Patent Landscape: The patent is part of a broader research landscape in thiazolidinedione derivatives.
- Valuation: The patent's value can be determined using cost, income, and market approaches.
- Legal Status: The patent has expired, making the technology publicly available.
FAQs
Q1: What are the primary therapeutic applications of the compounds described in US 5,002,953?
The compounds are primarily used for their hypoglycaemic and hypolipidaemic activities, treating disorders such as diabetes and hyperlipidemia.
Q2: How are the compounds of formula (I) prepared?
The patent includes a process for preparing these compounds, which involves specific chemical reactions and synthesis steps.
Q3: What is the significance of the classification of this patent under IPC categories?
The classification under IPC categories such as C07D277/00 and A61P3/00 helps in identifying the patent's relevance to specific fields of chemistry and medicine.
Q4: How can the value of this patent be determined?
The value can be determined using cost, income, and market approaches, considering the future benefits and market demand for similar patents.
Q5: What is the current legal status of US 5,002,953?
The patent has expired, meaning the exclusive rights to the invention are no longer in effect, and the technology is now in the public domain.
Sources
- US5002953A - Novel compounds - Google Patents
- United States Patent (19) - googleapis.com
- Patent Analytics | Intellectual Property Law
- The value of a patent - Perpetual Motion Patents
- Untitled - USPTO
